15
Apr

After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline has secured FDA approval for albiglutide, a new diabetes treatment that will contend for market share in a fast-crowding space.

…read more

Source: GlaxoSmithKline wins an FDA nod for its GLP-1 diabetes drug albiglutide

    

0 No comments